Fuda Cancer Hospital
Fuda Cancer Hospital
Chiny, Kanton
Esophageal cancer treatment cost in China runs from $100 to $600 for a diagnostic gastroscopy, while a surgical resection of the esophagus ranges from $26,500 to $49,500. Total expenses depend on cancer staging, the complexity of combined therapies, and whether the facility is public or private. International patients typically save 50-70% compared to US costs. Top treatment hubs include Guangzhou and Xiamen.
Typical Esophageal Cancer Treatment Costs in China
Bookimed Expert Insight: Patients with advanced thoracic malignancies benefit from precision radiotherapy at centers like Xiamen Humanity Hospital. Professor Liu Shixin specializes in IMRT and VMAT protocols for complex esophageal cases. For those seeking non-traditional options, Fuda Cancer Hospital provides over 10 types of minimally invasive therapies. This is ideal for patients who cannot tolerate standard chemotherapy. JCI-accredited facilities in China offer specialized oncology care for late-stage cases reaching over 30,000 international patients.
| Chiny | Turcja | Austria | |
| Radioterapia raka przełyku | od $14,500 | od $7,000 | od $20,000 |
| Radioterapia raka odbytnicy | od $11,500 | od $7,000 | od $12,000 |
| Ezofagektomia | od $18,500 | od $23,400 | od $30,000 |
| Chemioterapia w raku piersi | od $14,800 | od $1,200 | od $15,000 |
| Chemioterapia przy raku przełyku | od $12,500 | od $5,000 | od $12,000 |
Państwo nie płacą za usługi Bookimed. Ceny leczenia raka przełyku odpowiadają cennikowi kliniki. Płatność dokonywana jest bezpośrednio w klinice po przyjeździe. Dostępna jest płatność w ratach.
Bookimed dba o Państwa bezpieczeństwo. Współpracujemy tylko z klinikami spełniającymi wysokie międzynarodowe standardy w leczeniu raka przełyku. Posiadają one wymagane licencje do obsługi pacjentów międzynarodowych na całym świecie.
Bookimed oferuje bezpłatną pomoc i wsparcie. Osobisty koordynator medyczny pozostaje w kontakcie przed, w trakcie i po podróży. Nie będą Państwo sami w innym kraju podczas leczenia raka przełyku.
Professor Shixin Liu, MD, PhD, is the Discipline Leader of the Oncology Center. He is the former President of Jilin Provincial Cancer Hospital and former Director of the Cancer Prevention and Treatment Research Institute. He is a second-level professor and doctoral supervisor. He has received the State Council Special Government Allowance, the 4th National Famous Doctor (Outstanding Contribution) award, and the Model of Medical Ethics honor.
He specializes in the comprehensive diagnosis and treatment of malignant tumors. His focus is precision radiotherapy for thoracic and abdominal cancers. He is skilled in IMRT, VMAT, and SBRT for lung, esophageal, breast, and rectal cancers.
His leadership roles include Vice Chair of CMA Radiation Oncology, CACA Radiotherapy, and CACA Particle Therapy. He serves on the CSCO Standing Committee and as Vice Chair of the CSCO Radiation Oncology Expert Committee. He is Vice Chair of CPAM Radiation Oncology and a Standing Committee member of CSMEA. He chairs the Jilin Medical Association Radiation Oncology branch. He is on the editorial boards of the Chinese Journal of Radiation Oncology and the Practical Journal of Cancer.
China treats locally advanced esophageal cancer with a multidisciplinary approach combining neoadjuvant therapy and radical surgery. Over 90% of cases are squamous cell carcinoma. Standard care involves preoperative chemotherapy, chemoradiation, or immunotherapy to downstage tumors. Surgeons then perform esophagectomy with extensive lymph node dissection.
Bookimed Expert Insight: Chinese oncology centers demonstrate high proficiency in treating squamous cell carcinoma due to high domestic volumes. Fuda Cancer Hospital manages over 30,000 international patients. Specialized professors like Dr. Liu Shi Xin at Xiamen Humanity Hospital focus specifically on precision radiotherapy. This specialization often translates into more aggressive lymph node clearance protocols compared to Western clinics.
Patient Consensus: Patients emphasize that managing weight loss and nutrition is as vital as the cancer treatment itself. Many note that recovery after surgery is a long process requiring significant dietary adjustments.
Immunotherapy is the modern cornerstone for advanced esophageal cancer in China. It serves as primary first-line care for metastatic cases. Chinese protocols combine PD-1 inhibitors with chemotherapy to improve survival. This approach targets esophageal squamous cell carcinoma which is highly prevalent in the region.
Bookimed Expert Insight: While many global patients focus on brand-name drugs, JCI-accredited centers like Fuda Cancer Hospital utilize a massive volume of specialized domestic PD-1 inhibitors. These centers manage over 30,000 international patients. This high volume allows Chinese oncologists to refine combination protocols specifically for squamous cell carcinoma. They often integrate immunotherapy with specialized local treatments like microwave hyperthermia or cryosurgery.
Patient Consensus: Patients emphasize that biomarker testing for PD-L1 is a vital first step for eligibility. Many note that while daily side effects feel milder than chemo, they watch closely for sudden immune-related fatigue or rashes.
Minimally invasive surgery is widely available in Chinas premier hospitals and specialized centers. These institutions utilize robotic systems and advanced endoscopy for complex cases. High patient volumes allow surgical teams to refine these precision techniques. Some centers report significant results for late-stage cancer care.
Bookimed Expert Insight: Specialized oncology hospitals in China like Fuda Cancer Hospital frequently focus on over 10 different types of minimally invasive therapies. This variety suggests that Chinese centers often combine multiple localized treatments rather than relying on a single surgical approach. This strategy is particularly common for advanced or late-stage cancer cases.
Patient Consensus: Patients value the shorter recovery times of minimally invasive methods but emphasize checking a surgeons specific case volume. While robotic options are available, many note that preoperative planning is more critical than the technology used.
Cutting-edge clinical trials for esophageal cancer in China are highly accessible for patients at major academic centers. China manages over 50% of global cases. This high volume accelerates patient recruitment. Research institutions utilize specialized networks to match candidates with advanced protocols efficiently.
Bookimed Expert Insight: Data suggests that centralized care in cities like Guangzhou or Xiamen is vital for trial entry. JCI-accredited facilities like Fuda Cancer Hospital serve over 30,000 international patients. Experienced specialists like Dr. Liu Shi Xin at Xiamen Humanity Hospital coordinate complex precision radiotherapy. Patients should target these high-volume tertiary hospitals rather than local clinics to find active enrollment opportunities.
Patient Consensus: Patients note that trial windows move very fast during the staging process. They emphasize having all pathology and imaging reports translated before reaching out to major urban centers.
Traditional Chinese Medicine (TCM) integrates with conventional esophageal cancer treatment as a supportive therapy. It manages side effects from chemotherapy or radiation. Practitioners use acupuncture for nausea and pain. Herbal medicine may protect liver function. Patients must prioritize surgery or chemoradiation over traditional remedies.
Bookimed Expert Insight: Leading Chinese centers like Fuda Cancer Hospital serve over 30,000 international patients. They often replace standard systemic chemotherapy with over 10 types of minimally invasive therapies. These include cryosurgery and vascular interventional therapy. If you seek TCM, choose hospitals with these advanced technologies. They provide a more controlled environment for integrative care than standalone herbal clinics.
Patient Consensus: Patients note that TCM helps with appetite and fatigue but warn against using it alone. Many emphasize that delaying standard treatment for herbal cures often leads to regret as the cancer progresses.